Top

Cancer Cell International

Published in:

Open Access 01-12-2018 | Primary research

MiR-218 regulates epithelial–mesenchymal transition and angiogenesis in colorectal cancer via targeting CTGF

Authors: Weijian Lun, Xiongjian Wu, Qiliang Deng, Fachao Zhi

Published in: Cancer Cell International | Issue 1/2018

Abstract

Background

Endothelial-to-mesenchymal transition (EMT) and angiogenesis play important roles in colorectal cancer (CRC) development. Connective tissue growth factor (CTGF) has been reported to promote several kinds of cancer progression and miR-218 has been identified as a tumor suppressor miRNA. However, little is known about the function of miR-218 in CRC. Here we investigated the effects of miR-218 on EMT and angiogenesis process in CRC cells. As well, the relation between miR-218 and CTGF was identified. The mechanism of miR-218’s function was illustrated.

Methods

CRC cell lines were transfected with miR-218 mimics. Proliferation, migration and angiogenesis were identified by MTT assay, Transwell assay, colony formation assay and tube formation assay. Protein and mRNA expression levels of associated genes were measured by Western blotting and RT-PCR. Dual luciferase assay was used to determine the relation of miR-218 and CTGF.

Results

miR-218 was down-regulated in CRC cell lines and over expression of miR-218 could significantly inhibit EMT and angiogenesis. CTGF was a direct target of miR-218. Up regulation of CTGF level after miR-218 transfection could sufficiently rescue the suppression effects on EMT and angiogenesis.

Conclusion

miR-218 directly targets CTGF and inhibits its expression, leading to suppression on EMT and angiogenesis of CRC cells. miR-218 might be used as potential therapeutic strategy for CRC treatment.

Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Liu FF. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011;71(6):2381–91. https://doi.org/10.1158/0008-5472.CAN-10-2754.CrossRefPubMed

Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5. https://doi.org/10.1038/nature02871.CrossRefPubMed

Bennewith KL, Huang X, Ham CM, Graves EE, Erler JT, Kambham N, Giaccia AJ. The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 2009;69(3):775–84. https://doi.org/10.1158/0008-5472.CAN-08-0987.CrossRefPubMedPubMedCentral

Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007;23:175–205. https://doi.org/10.1146/annurev.cellbio.23.090506.123406.CrossRefPubMed

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66. https://doi.org/10.1038/nrc1997.CrossRefPubMed

Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, Batlle E. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22(5):571–84. https://doi.org/10.1016/j.ccr.2012.08.013.CrossRefPubMedPubMedCentral

Capparelli C, Whitaker-Menezes D, Guido C, Balliet R, Pestell TG, Howell A, Sotgia F. CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle. 2012;11(12):2272–84. https://doi.org/10.4161/cc.20717.CrossRefPubMedPubMedCentral

Chen B, Jin H, Wu K. Potential role of vascular targeted therapy to combat against tumor. Expert Opin Drug Deliv. 2009;6(7):719–26. https://doi.org/10.1517/17425240903018871.CrossRefPubMed

Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005;438(7070):937–45. https://doi.org/10.1038/nature04479.CrossRefPubMed

10.

Edwards LA, Woolard K, Son MJ, Li A, Lee J, Ene C, Fine HA. Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst. 2011;103(15):1162–78. https://doi.org/10.1093/jnci/djr224.CrossRefPubMedPubMedCentral

11.

Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273–86. https://doi.org/10.1038/nrd2115.CrossRefPubMed

12.

Hao Y, Yang J, Yin S, Zhang H, Fan Y, Sun C, Xi JJ. The synergistic regulation of VEGF-mediated angiogenesis through miR-190 and target genes. RNA. 2014;20(8):1328–36. https://doi.org/10.1261/rna.044651.114.CrossRefPubMedPubMedCentral

13.

He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK, Yu J. MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med. 2013;18:1491–8. https://doi.org/10.2119/molmed.2012.00304.PubMedCrossRef

14.

Ilm K, Fuchs S, Mudduluru G, Stein U. MACC1 is post-transcriptionally regulated by miR-218 in colorectal cancer. Oncotarget. 2016;7(33):53443–58. https://doi.org/10.18632/oncotarget.10803.CrossRefPubMedPubMedCentral

15.

Jun F, Hong J, Liu Q, Guo Y, Liao Y, Huang J, Shen L. Epithelial membrane protein 3 regulates TGF-beta signaling activation in CD44-high glioblastoma. Oncotarget. 2017;8(9):14343–58. https://doi.org/10.18632/oncotarget.11102.CrossRefPubMed

16.

Kalluri R, Weinberg RA. The basics of epithelial–mesenchymal transition. J Clin Invest. 2009;119(6):1420–8. https://doi.org/10.1172/JCI39104.CrossRefPubMedPubMedCentral

17.

Kogo R, How C, Chaudary N, Bruce J, Shi W, Hill RP, Liu FF. The microRNA-218 ~ Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer. Oncotarget. 2015;6(2):1090–100. https://doi.org/10.18632/oncotarget.2836.CrossRefPubMed

18.

Lau LF. Cell surface receptors for CCN proteins. J Cell Commun Signal. 2016;10(2):121–7. https://doi.org/10.1007/s12079-016-0324-z.CrossRefPubMedPubMedCentral

19.

Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.CrossRefPubMed

20.

Liu LY, Han YC, Wu SH, Lv ZH. Expression of connective tissue growth factor in tumor tissues is an independent predictor of poor prognosis in patients with gastric cancer. World J Gastroenterol. 2008;14(13):2110–4.CrossRefPubMedPubMedCentral

21.

Moussad EE, Brigstock DR. Connective tissue growth factor: what’s in a name? Mol Genet Metab. 2000;71(1–2):276–92. https://doi.org/10.1006/mgme.2000.3059.CrossRefPubMed

22.

Nishikawa R, Goto Y, Sakamoto S, Chiyomaru T, Enokida H, Kojima S, Seki N. Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. Cancer Sci. 2014;105(7):802–11. https://doi.org/10.1111/cas.12441.CrossRefPubMedPubMedCentral

23.

Omoto S, Nishida K, Yamaai Y, Shibahara M, Nishida T, Doi T, Takigawa M. Expression and localization of connective tissue growth factor (CTGF/Hcs24/CCN2) in osteoarthritic cartilage. Osteoarthritis Cartilage. 2004;12(10):771–8. https://doi.org/10.1016/j.joca.2004.06.009.CrossRefPubMed

24.

Perbal B. CCN proteins: multifunctional signalling regulators. Lancet. 2004;363(9402):62–4. https://doi.org/10.1016/S0140-6736(03)15172-0.CrossRefPubMed

25.

Sala-Torra O, Gundacker HM, Stirewalt DL, Ladne PA, Pogosova-Agadjanyan EL, Slovak ML, Radich JP. Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia. Blood. 2007;109(7):3080–3. https://doi.org/10.1182/blood-2006-06-031096.PubMedPubMedCentralCrossRef

26.

Shany S, Sigal-Batikoff I, Lamprecht S. Vitamin D and myofibroblasts in fibrosis and cancer: at cross-purposes with TGF-beta/SMAD signaling. Anticancer Res. 2016;36(12):6225–34. https://doi.org/10.21873/anticanres.11216.CrossRefPubMed

27.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332.CrossRefPubMed

28.

Sundlisaeter E, Dicko A, Sakariassen PO, Sondenaa K, Enger PO, Bjerkvig R. Lymphangiogenesis in colorectal cancer–prognostic and therapeutic aspects. Int J Cancer. 2007;121(7):1401–9. https://doi.org/10.1002/ijc.22996.CrossRefPubMed

29.

Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial–mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90. https://doi.org/10.1016/j.cell.2009.11.007.CrossRefPubMed

30.

Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–42. https://doi.org/10.1038/nrm1835.CrossRefPubMed

31.

Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Fan D. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010;6(3):e1000879. https://doi.org/10.1371/journal.pgen.1000879.CrossRefPubMedPubMedCentral

32.

Tu Y, Gao X, Li G, Fu H, Cui D, Liu H, Zhang Y. MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res. 2013;73(19):6046–55. https://doi.org/10.1158/0008-5472.CAN-13-0358.CrossRefPubMed

33.

Ubink I, Verhaar ER, Kranenburg O, Goldschmeding R. A potential role for CCN2/CTGF in aggressive colorectal cancer. J Cell Commun Signal. 2016;10(3):223–7. https://doi.org/10.1007/s12079-016-0347-5.CrossRefPubMedPubMedCentral

34.

Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res. 2001;61(24):8917–23.PubMed

35.

Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, Black K, Koeffler HP. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res. 2004;10(6):2072–81.CrossRefPubMed

36.

Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005;65(19):8887–95. https://doi.org/10.1158/0008-5472.CAN-05-1702.CrossRefPubMed

37.

Yang HY, Ma D, Liu YR, Hu X, Zhang J, Wang ZH, Shao ZM. Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer. Sci Rep. 2017;7(1):1134. https://doi.org/10.1038/s41598-017-00663-1.CrossRefPubMedPubMedCentral

38.

Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28(1–2):15–33. https://doi.org/10.1007/s10555-008-9169-0.CrossRefPubMed

39.

Zhang H, Hao Y, Yang J, Zhou Y, Li J, Yin S, Xi JJ. Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat Commun. 2011;2:554. https://doi.org/10.1038/ncomms1555.CrossRefPubMed

40.

Zhang X, Dong J, He Y, Zhao M, Liu Z, Wang N, Tie J. miR-218 inhibited tumor angiogenesis by targeting ROBO1 in gastric cancer. Gene. 2017;615:42–9. https://doi.org/10.1016/j.gene.2017.03.022.CrossRefPubMed

Title: MiR-218 regulates epithelial–mesenchymal transition and angiogenesis in colorectal cancer via targeting CTGF
Authors: Weijian Lun
Xiongjian Wu
Qiliang Deng
Fachao Zhi
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2018
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-018-0575-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

rs61991156 in miR-379 is associated with low capability of glycolysis of gastric cancer by enhanced regulation of PKM2

Targeting FBPase is an emerging novel approach for cancer therapy

Polymorphism in lncRNA AC016683.6 and its interaction with smoking exposure on the susceptibility of lung cancer

Vasodilator-stimulated phosphoprotein (VASP), a novel target of miR-4455, promotes gastric cancer cell proliferation, migration, and invasion, through activating the PI3K/AKT signaling pathway

PEG10 as an oncogene: expression regulatory mechanisms and role in tumor progression

Prognostic and clinicopathological significance of long noncoding RNA HOXA11-AS expression in human solid tumors: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer